Pre-made Romilkimab benchmark antibody ( Bispecific Dual Variable Domain IG, anti-IL13;IL4 therapeutic antibody, Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-492
Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Romilkimab (SAR156597), however, “is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis,” the researchers explain.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody|
|Format||Bispecific Dual Variable Domain IG|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Discontinued||Idiopathic pulmonary fibrosis|